Markets | |
In the span of a couple of weeks, there has been good news and bad news about Cronos Group (NASDAQ:CRON). The good news came on February 11 when the company received news that suggests it may be one of the most well-positioned cannabis stocks for the long haul.
The bad news came on February 26 wh... Read the Full Story >> |
|
From Our PartnersShocking news out of the marijuana industry, and Wall Street Insiders are going crazy. A massive 1.4 million sq. ft. super-greenhouse is coming online and could send a little-known 50-cent marijuana stock soaring! | Click here for more details... |
|
Markets | | Despite the coronavirus's best efforts to take down the stock market with no prisoners in recent days, TJX Companies (NYSE: TJX) had just the remedy shareholders were looking for. The off-price department store released red hot Q4 earnings on Wednesday that crushed analyst expectations and sen... Read the Full Story >> |
|
Markets | | I Can’t Say I Didn’t See That One Coming
Goldman Sachs (GS) shocked the market this morning when lead-analyst David Kostin downgraded 2020 EPS growth to zero. I say shocked because the market was already spooked. The spreading coronavirus threatens to shut down the global economy in a w... Read the Full Story >> |
|
|
Markets | |
There's a dichotomy between mall-focused retail and stand-alone store retail that seems to be growing with each new earnings report that emerges. While stores like Foot Locker and American Eagle falter, and perennial anchor stores from Sears (OTCMKTS: SHLDQ) to Macy's (NYSE: M) to JCPenney (NYSE: ... Read the Full Story >> |
|
Markets | | Many of the most successful investors of all time have lived and been invested throughout periods of extreme volatility. This tells us that instead of reacting dramatically and selling everything during a big down day Read the Full Story >> |
|
From Our PartnersA "rigged" way to trade the market for 70-90 percent odds and positive risk to reward metrics. | Watch Video Report Here |
|
The Early Bird Stock Of The Day Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. | View Today's Stock Pick |
|